Impaired fibrinolysis determines the outcome of percutaneus transluminal coronary angioplasty (PTCA)

European Journal of Clinical Investigation

Volumn 31, Issue 7, 2001, Pages 586-592

  Fornitz, G G ^a,b   Nielsen, P ^a   Amtorp, O ^a   Kassis, E ^a   Abildgard U ^a   Sloth, C ^a   Winther, K ^a   Orskov, H ^a   Dalsgard J ^a   Husted, S ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Gentofte Hospital ^*  (Denmark)

Author keywords

Fibrinolysis; PTCA; Restenosis

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY OBSTRUCTION; CORONARY SINUS; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; RESTENOSIS; THROMBOCYTE FUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BETA-THROMBOGLOBULIN; CORONARY DISEASE; FIBRINOLYSIS; FOLLOW-UP STUDIES; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET-DERIVED GROWTH FACTOR; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034947317     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2001.00855.x     Document Type: Article

References (32)

1. Incidence of restenosis after successful coronary angioplasty: A time-related phenomen; a quantitative angiographic study in 342 consecutive patients at 1, 2, 3 and 4 months
2. Restenosis after percutaneous transluminal coronary angioplastry (PTCA): A report from the PTCA registry of National Heart, Lung, and Blood Institute
3. Percutaneous transluminal coronary angioplasty for chronic total arterial occlusion
4. Recurrence rate after successful coronary angioplasty
5. Restenosis after successful coronary angioplasty in patients with single-vessel disease
6. Restenosis after successful percutaneous transluminal coronary angioplasty. Serial angiographic follow-up of 229 patients
7. The pathogenesis of atherosclerosis: A perspective for the 1990s
8. Kinetics of cellular proliferation after arterial injury
9. Nonoperative dilation of coronary-artery stenosis: Percutaneous transluminal coronary angioplasty
10. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model
11. The pathogenesis of atherosclerosis - An update
12. Coronary atherosclerosis: Current therapeutic approaches and future trends
13. Vascular permeation of platelet factor 4 after endothelial injury
14. The platelet derived growth factor
15. Liberation of the immunoreactive somotomedin C from its binding proteins by proteolytic enzymes and heparin
16. Peptide inhibition of myointimal proliferation by angiopeptin, a somostatin analoge
17. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty
18. Platelet abnormalities in ischemic heart disease
19. In vivo platelet activation following myocardial infarction and acute coronary ischaemia
20. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
21. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneus transluminal coronary angioplasty (PTCA)
22. Myocardial viability in patients with Q wave myocardial infarction and no residual ischemia
23. Report of the joint ISFC/WHO task force on coronary angioplasty
24. Fibrinogen after coronary angioplasty as a risk factor for restenosis
25. ECAT angina pectoris study. Associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography
26. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
27. The pathogenesis of atherosclerosis
28. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis
29. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significant reduced risk for coronary restenosis
30. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty
31. The hemostatic system and coronary artery disease
32. Impaired fibrinolytic capacity and tissue plasminogen activator in patients with restenosis after percutaneus transluminal coronary angioplasty (PTCA)